NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Survodutide

Survodutide

An investigational dual glucagon and GLP-1 receptor agonist with reported phase 2 weight-loss and MASH data; not approved.

Overview

Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Publicly reported phase 2 results describe weight loss and improvements in liver-histology endpoints. It is not an approved drug.

Mechanism

The dual-agonist design combines GLP-1-mediated appetite suppression and glycemic benefit with glucagon-receptor-driven increases in energy expenditure and effects on hepatic lipid metabolism, aiming to reduce body weight and liver fat simultaneously.

Expected Effects

  • Dose-dependent weight loss in the reported phase 2 obesity program
  • Higher rates of MASH resolution and fibrosis improvement versus placebo in reported phase 2 histology data
  • Glycemic improvements in participants with type 2 diabetes

Side Effects & Tolerability

As with the incretin class, gastrointestinal events such as nausea, vomiting, and diarrhea are the most common adverse effects and drive dose-titration strategies. Cardiovascular and long-term safety data await larger trials.

Storage

As an investigational research peptide, store lyophilized material cold and desiccated, protected from light and moisture, and follow the supplier certificate of analysis.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.